Cargando…
Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies
Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, is characterized by a high mortality rate and poor prognosis. Current treatments for PDAC, are ineffective due to a prominent immunosuppressive PDAC tumor microenvironment (TME). Although B lymphocytes are highly inf...
Autores principales: | Senturk, Zeynep Nur, Akdag, Isilay, Deniz, Bahar, Sayi-Yazgan, Ayca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076755/ https://www.ncbi.nlm.nih.gov/pubmed/37033931 http://dx.doi.org/10.3389/fimmu.2023.1152551 |
Ejemplares similares
-
Helicobacter-stimulated IL-10-producing B cells suppress differentiation of lipopolysaccharide/Helicobacter felis-activated stimulatory dendritic cells
por: ALTUNÖZ, Doğuş, et al.
Publicado: (2021) -
Regulatory T Cells as Immunotherapy
por: Singer, Benjamin D., et al.
Publicado: (2014) -
Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy
por: Qi, Xiaochen, et al.
Publicado: (2022) -
Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells
por: NABA, Noel Mopouguini, et al.
Publicado: (2020) -
Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy
por: Wei, Qi, et al.
Publicado: (2022)